Eli Lilly forecast annual profit largely above Wall Street estimates on Thursday, as it prepares to launch its popular ...
Eli Lilly forecast annual profit largely above Wall Street estimates on Thursday, providing some relief to investors after ...
In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...
Eli Lilly forecasts 2025 profit largely above estimates on launch of weight-loss drug in new markets
Eli Lilly forecast annual profit largely above Wall Street estimates on Thursday, banking on the launch of its popular ...
Too many young people are prescribed pills for mental illness. Are we repeating history with GLP-1s?
Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales ...
A new study examines how cost, side effects, and other factors influence whether people stop GLP-1s, while Noom cuts staff to ...
When Jeanne began to seriously consider taking Zepbound, one of the new-generation weight-loss drugs, she had the briefest of ...
Nearly 2 in 3 people without diabetes quit popular weight loss drugs such as Ozempic or Victoza within one year, according to ...
Americans are split on using weight loss drugs such as Ozempic and Wegovy to treat obesity or weight-related conditions, ...
The use of blockbuster weight loss drugs has surged among young women, for whom the treatments can often be "liberating." ...
The EGOT winner railed against an ad that's circulating on social media with a manipulated version of her promoting "bad ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results